Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 7/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29945766 | 1.00 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19RECQLAR | |
| SCHEMBL16960634 | 0.86 | AR (0.44) | ARPDK2 | |
| SCHEMBL16962054 | 0.81 | AR (0.40) | ARPDK2ALDH1A1P2RX7 | |
| SCHEMBL16959027 | 0.80 | AR (0.39) | ARPDK2 | |
| SCHEMBL25983090 | 0.78 | AR (0.46) | ARPDK2 | |
| SCHEMBL8221389 | 0.77 | NOTUM (0.47) | CYP1A2CYP2C9CYP2C19RECQLPOLB | |
| SCHEMBL180961 | 0.76 | ALDH1A1 (0.48) | POLBLMNAALDH1A1GALR3RAB9A | |
| SCHEMBL9522265 | 0.75 | MAPT (0.44) | CYP1A2CYP2C9CYP2C19RECQLPOLB | |
| SCHEMBL2001643 | 0.75 | LMNA (0.46) | PDK2LMNATAS2R14NOTUM | |
| SCHEMBL30148729 | 0.75 | MAPT (0.44) | CYP1A2CYP2C9CYP2C19RECQLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| EP-4358963-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127429-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | CYP1A2 4661/4885CYP2C9 4483/4885CYP2C19 4810/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | CYP1A2 4781/4885CYP2C9 4835/4885CYP2C19 4880/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | CYP1A2 4753/4885CYP2C9 4799/4885CYP2C19 4871/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | CYP1A2 4781/4885CYP2C9 4835/4885CYP2C19 4880/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | CYP1A2 4781/4885CYP2C9 4835/4885CYP2C19 4880/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | CYP1A2 4753/4885CYP2C9 4799/4885CYP2C19 4871/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | CYP1A2 4753/4885CYP2C9 4799/4885CYP2C19 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.